Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study

다국어 초록 (Multilingual Abstract)

Purpose: We report short-term patency outcomes of a proof of concept study conducted to determine the efficacy of drug-eluting stent (DES) for the treatment of arteriovenous fistula (AVF) stenosis in hemodialysis patients.
Materials and Methods: This is a single-center, retrospective observational study involving 10 patients with AVF dysfunction treated with DESs between January 2017 and December 2017. The primary outcome was AVF patency confirmed by sonographic and clinical assessment at 1 month and 6 to 9 months after treatment.
Results: A total of 12 DESs were deployed in 10 patients with dysfunctional AVF (radiocephalic: 7, brachiocephalic: 3). During the early follow up (mean: 28.6 days), primary access circuit and DES patency was 100%, with an average volume flow rate of 886.4 mL/min. Nine patients were available for short-term follow up (mean: 202.4 days; 1 unrelated death), with a mean volume flow rate of 1,048.9 mL/min.
The primary DES patency was 7/9 (77.8%), and 3 patients required angioplasty at other parts of the circuit (primary access circuit patency: 4/9 [44.4%]). The assisted primary access circuit patency was 77.8%. In 2 patients, the ultrasound revealed that the DESs were thrombosed without any antecedent stenosis; they were salvaged with angioplasty. Both patients previously underwent 2 DESs implanted and recently stopped dual antiplatelet therapy. B-mode sonographic assessment at all timepoints showed minimal intimal ingrowth on the stent struts.
Conclusion: This study demonstrates acceptable short-term patency for DESs in the treatment of AVF stenosis. Dual antiplatelet therapy is probably mandatory in the short term.

참고문헌 (Reference)

1 Çildağ MB, "The primary patency of drug-eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses" 34 : 700-704, 2016

2 Khawaja AZ, "Systematic review of drug eluting balloon angioplasty for arteriovenous haemodialysis access stenosis" 17 : 103-110, 2016

3 Ulloa JG, "Stent salvage of arteriovenous fistulas and grafts" 48 : 234-238, 2014

4 McLennan G, "Stent and stent-graft use in arteriovenous dialysis access" 33 : 10-14, 2016

5 Kronlage M, "Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries" 11 : 2937-2945, 2017

6 Sidawy AN, "Recommended standards for reports dealing with arteriovenous hemodialysis accesses" 35 : 603-610, 2002

7 Kitrou PM, "Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae : one-year results of a prospective randomized controlled trial" 26 : 348-354, 2015

8 Katsanos K, "Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access:6-month interim results from a prospective randomized controlled trial" 19 : 263-272, 2012

9 Massmann A, "Paclitaxel-coated balloon angioplasty for symptomatic central vein restenosis in patients with hemodialysis fistulas" 22 : 74-79, 2015

10 Swinnen JJ, "Paclitaxel drug-eluting balloons to recurrent in-stent stenoses in autogenous dialysis fistulas : a retrospective study" 16 : 388-393, 2015

11 Swinnen JJ, "Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses" 20 : 260-269, 2019

12 Dinh K, "Mortality after paclitaxel-coated device use in dialysis access : a systematic review and meta-analysis" 26 : 600-612, 2019

13 Swinnen J, "Juxta-anastomotic stenting with aggressive angioplasty will salvage the native radiocephalic fistula for dialysis" 61 : 436-442, 2015

14 Agarwal AK, "How is arteriovenous fistula longevity best prolonged? : the role of percutaneous balloon angioplasty" 28 : 27-29, 2015

15 Yevzlin AS, "How is arteriovenous fistula longevity best prolonged? : the role of endovascular stents" 28 : 29-32, 2015

16 Chang CJ, "Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty : implication in prevention of restenosis" 43 : 74-84, 2004

17 Guyatt GH, "Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines" 141 (141): 7S-47S, 2012

18 Ozkan B, "Endovascular stent placement of juxtaanastomotic stenosis in native arteriovenous fistula after unsuccessful balloon angioplasty" 10 : 133-139, 2013

19 Sharma A, "Duration of dual antiplatelet therapy following drug-eluting stent implantation : a systemic review and meta-analysis of randomized controlled trials with longer follow up" 90 : 31-37, 2017

20 Laird JR, "Drug-eluting stents in the superficial femoral artery : the long and winding road" 133 : 1435-1437, 2016

21 Boitet A, "Drug-coated balloon angioplasty for dialysis access fistula stenosis" 29 : 178-185, 2016

22 Trerotola SO, "Drug coated balloon angioplasty in failing AV fistulas : a randomized controlled trial" 13 : 1215-1224, 2018

23 Duque JC, "Dialysis arteriovenous fistula failure and angioplasty : intimal hyperplasia and other causes of access failure" 69 : 147-151, 2017

24 Kitrou P, "Cutting balloons, covered stents and paclitaxel-coated balloons for the treatment of dysfunctional dialysis access" 13 : 1119-1126, 2016

25 Roy-Chaudhury P, "Biology of arteriovenous fistula failure" 20 : 150-163, 2007

26 Yang JK, "Antiplatelet therapy before, during, and after extremity revascularization" 60 : 1085-1091, 2014

27 Morice MC, "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization" 346 : 1773-1780, 2002

28 Gray WA, "A polymercoated, paclitaxel-eluting stent (Eluvia)versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL):a randomised, non-inferiority trial" 392 : 1541-1551, 2018

29 Thomas SD, "A comprehensive renal vascular access clinic results in improved patient outcomes and reduced costs" 88 : 185-190, 2018

30 National Kidney Foundation, "2006Updates to clinical practice guidelines and recommendations: vascular access"